Table 1.
Baseline characteristics including clinical and laboratory parameters
| HIV-infected subjects (n=33) |
Control Subjects (n=35) | p | |
|---|---|---|---|
|
| |||
| Age (years) | 45.2 (41.8, 48.7) | 46.9 (42.9, 50.9) | 0.52 |
|
| |||
| Sex n (%) | |||
| Male | 19 (57) | 19(55) | 0.97 |
| Female | 14(43) | 16(45) | 0.89 |
|
| |||
| Ethnicity n(%) | |||
| White | 16(48) | 30(85) | <0.0001 |
| Black | 14(42) | 2(5) | |
| Other | 3(3) | 3(8) | |
|
| |||
| Body surface area (m2) | 1.81 (1.76, 1.87) | 1.88 (1.79,1.96) | 0.22 |
|
| |||
| Blood pressure (mmHg) | |||
| Systolic | 123.7 (120.0, 127.4) | 121.3 (117.5, 125.2) | 0.38 |
| Diastolic | 76.1 (73.3, 79.0) | 76.2 (73.8, 78.6) | 0.97 |
|
| |||
| Total Cholesterol (mmol/L) | 4.7 (4.5, 4.9) | 4.9 (4.6, 5.2) | 0.34 |
|
| |||
| 10-year coronary risk (%) | 3.97 (2.58, 5.36) | 3.72 (2.5, 4.9) | 0.78 |
|
| |||
| HIV disease related parameters | |||
|
| |||
| Baseline CD4 cell count (cells/uL) | 638.48 (556.72, 720.25) | N/A | |
|
| |||
| Nadir CD4 cell count (cells/uL) | 276.36 (207.40, 345.33) | N/A | |
|
| |||
| Baseline plasma HIV RNA level <50 copies/mL n(%) |
33 (100) | N/A | |
|
| |||
| Years since HIV diagnosis | 8.82 (7.27, 10.37) | N/A | |
|
| |||
| Years on cART | 7.5 (6.0, 9.0) | N/A | |
|
| |||
| cART therapy at screening n(%) | |||
| NNRTI based | 24 (72) | N/A | |
| PI based | 9 (28) | N/A | |
|
| |||
| NRTI therapy at screening n(%) | |||
| Tenofovir based | 24 (72) | N/A | |
| Abacavir based | 6(18) | N/A | |
| Zidovudine based | 3 (9) | N/A | |
Values are numbers for categorical variables or mean (95% confidence interval) for continuous variables. cART indicates combine antiretroviral therapy; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.